Concert Pharmaceuticals Garners $37,000,000 Series C Funding

  • Feed Type
  • Date
    4/30/2008
  • Company Name
    Concert Pharmaceuticals
  • Mailing Address
    99 Hayden Avenue Lexington, MA 02421
  • Company Description
    Concert Pharmaceuticals, a privately held pharmaceutical company, is focused on developing novel small molecule drugs for unmet medical needs. Concert utilizes its advanced methodology to rapidly create potent bioavailable drug candidates.
  • Website
    http://www.concertpharma.com/
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $37,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    The Company intends to use the proceeds to further advance its deuterium chemistry platform and product pipeline.
  • M&A Terms
  • Venture Investor
    Undisclosed
  • Venture Investor
    Adage Capital Management
  • Venture Investor
    Three Arch Partners
  • Venture Investor
    TVM Capital
  • Venture Investor
    Skyline Ventures
  • Venture Investor
    Flagship Ventures
  • Venture Investor
    Brookside Capital
  • Venture Investor
    Greylock Partners
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    QVT Fund LP

By posting a comment, you agree to our terms and conditions.